{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:43:27Z","timestamp":1792579407216,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00702-025-03053-4","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:34:43Z","timestamp":1761971683000},"page":"2891-2906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of COMT-inhibitors in parkinson\u2019s disease: a phase-IV comparative study on adverse events of Tolcapone, Entacapone and Opicapone"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-8020","authenticated-orcid":false,"given":"Pasquale Maria","family":"Pecoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Paola","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2083-3241","authenticated-orcid":false,"given":"Francesco","family":"Bugamelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-757X","authenticated-orcid":false,"given":"Lazzaro","family":"di Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"8","key":"3053_CR1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","volume":"55","author":"CH Adler","year":"1998","unstructured":"Adler CH, Singer C, O\u2019Brien C et al (1998) Randomized, placebo-controlled study of Tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 55(8):1089\u20131095","journal-title":"Arch Neurol"},{"key":"3053_CR2","unstructured":"Administration FaD FDA Talk Paper. New Warnings for Parkinson\u2019s Drug, Tasmar.\u00a0In: US Department of Health and Human Services, Public Health Service 5600 Fishers Lane Rockville, MD 20857 Press Office UD"},{"issue":"7","key":"3053_CR3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/17425255.2013.789018","volume":"9","author":"JA Ag\u00fandez","year":"2013","unstructured":"Ag\u00fandez JA, Garc\u00eda-Mart\u00edn E, Alonso-Navarro H, Jim\u00e9nez-Jim\u00e9nez FJ (2013) Anti-Parkinson\u2019s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 9(7):859\u2013874","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3053_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","volume":"77","author":"CA Artusi","year":"2021","unstructured":"Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L (2021) Safety and efficacy of Tolcapone in Parkinson\u2019s disease: systematic review. Eur J Clin Pharmacol 77:817\u2013829","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3053_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/syn.10034","volume":"43","author":"R Ceravolo","year":"2002","unstructured":"Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ (2002) 18F-dopa PET evidence that Tolcapone acts as a central COMT inhibitor in parkinson\u2019s disease. Synapse 43(3):201\u2013207","journal-title":"Synapse"},{"key":"3053_CR6","doi-asserted-by":"crossref","unstructured":"Bachrach U, Saxena AK, Saxena M et al (1992) Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. In: Progress Drug Research\/Fortschritte Der Arzneimittelforschung\/Progr\u00e8s Des Recherches Pharmaceutiques, pp. 291\u2013350","DOI":"10.1007\/978-3-0348-7144-0_9"},{"key":"3053_CR7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.neuropharm.2013.10.014","volume":"77","author":"M Bonif\u00e1cio","year":"2014","unstructured":"Bonif\u00e1cio M, Sutcliffe J, Torr\u00e3o L, Wright L, Soares-da-Silva P (2014) Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology 77:334\u2013341","journal-title":"Neuropharmacology"},{"issue":"3","key":"3053_CR8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","volume":"13","author":"MJ Bonif\u00e1cio","year":"2007","unstructured":"Bonif\u00e1cio MJ, Palma PN, Almeida L, Soares-da\u2010Silva P (2007) Catechol\u2010O\u2010methyltransferase and its inhibitors in parkinson\u2019s disease. CNS Drug Rev 13(3):352\u2013379","journal-title":"CNS Drug Rev"},{"issue":"1","key":"3053_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","volume":"4","author":"N Borges","year":"2005","unstructured":"Borges N (2005) Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 4(1):69\u201373","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"3053_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/425589","volume":"75","author":"J Chen","year":"2004","unstructured":"Chen J, Lipska BK, Halim N et al (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75(5):807\u2013821","journal-title":"Am J Hum Genet"},{"issue":"3","key":"3053_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00002826-200005000-00003","volume":"23","author":"DJ Chong","year":"2000","unstructured":"Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR (2000) The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with parkinson\u2019s disease. Clin Neuropharmacol 23(3):143\u2013148","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"3053_CR12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.20410","volume":"20","author":"M Contin","year":"2005","unstructured":"Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A (2005) Genetic polymorphism of catechol-O\u2010methyltransferase and levodopa pharmacokinetic\u2013pharmacodynamic pattern in patients with parkinson\u2019s disease. Mov Disord 20(6):734\u2013739","journal-title":"Mov Disord"},{"issue":"38","key":"3053_CR13","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1523\/JNEUROSCI.0665-07.2007","volume":"27","author":"L Yavich","year":"2007","unstructured":"Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, M\u00e4nnist\u00f6 PT (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27(38):10196\u201310209","journal-title":"J Neurosci"},{"issue":"2","key":"3053_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2004.06.033","volume":"214","author":"AES Doyle","year":"2004","unstructured":"Doyle AES, Goodman JE, Silber PM, Yager JD (2004) Catechol-O-methyltransferase low activity genotype (COMTLL) is associated with low levels of COMT protein in human hepatocytes. Cancer Lett 214(2):189\u2013195","journal-title":"Cancer Lett"},{"issue":"2","key":"3053_CR15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/08919887221103580","volume":"36","author":"A Dwivedi","year":"2023","unstructured":"Dwivedi A, Dwivedi N, Kumar A et al (2023) Association of catechol-O-methyltransferase gene rs4680 polymorphism and Levodopa induced dyskinesia in Parkinson\u2019s disease: a meta-analysis and systematic review. J Geriatr Psychiatr Neurol 36(2):98\u2013106","journal-title":"J Geriatr Psychiatr Neurol"},{"issue":"6","key":"3053_CR16","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1210\/jcem.83.6.4870","volume":"83","author":"G Eisenhofer","year":"1998","unstructured":"Eisenhofer G, Keiser H, Friberg P et al (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83(6):2175\u20132185","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3053_CR17","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ki.1997.390","volume":"52","author":"A-C Ekl\u00f6f","year":"1997","unstructured":"Ekl\u00f6f A-C, Holtb\u00e4ck U, Sundel\u00f6f M, Chen S, Aperia A (1997) Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+, K+-ATPase. Kidney Int 52(3):742\u2013747","journal-title":"Kidney Int"},{"issue":"1\u20132","key":"3053_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0378-4347(99)00125-5","volume":"729","author":"T Ellingson","year":"1999","unstructured":"Ellingson T, Duddempudi S, Greenberg BD, Hooper D, Eisenhofer G (1999) Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. J Chromatogr B Biomed Sci Appl 729(1\u20132):347\u2013353","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"10","key":"3053_CR19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/mds.27475","volume":"33","author":"M Fabbri","year":"2018","unstructured":"Fabbri M, Ferreira JJ, Lees A et al (2018) Opicapone for the treatment of Parkinson\u2019s disease: a review of a new licensed medicine. Mov Disord 33(10):1528\u20131539","journal-title":"Mov Disord"},{"issue":"21","key":"3053_CR20","doi-asserted-by":"crossref","first-page":"e1849","DOI":"10.1212\/WNL.0000000000005557","volume":"90","author":"JJ Ferreira","year":"2018","unstructured":"Ferreira JJ, Lees AJ, Poewe W et al (2018) Effectiveness of Opicapone and switching from Entacapone in fluctuating Parkinson disease. Neurology 90(21):e1849\u2013e1857","journal-title":"Neurology"},{"issue":"2","key":"3053_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P (2016) Opicapone as an adjunct to Levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165","journal-title":"Lancet Neurol"},{"issue":"7","key":"3053_CR22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/ene.13914","volume":"26","author":"JJ Ferreira","year":"2019","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da\u2010Silva P (2019) Long-term efficacy of Opicapone in fluctuating parkinson\u2019s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 26(7):953\u2013960","journal-title":"Eur J Neurol"},{"issue":"3","key":"3053_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s40120-022-00371-7","volume":"11","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O et al (2022) Opicapone as an add-on to Levodopa in patients with parkinson\u2019s disease without motor fluctuations: rationale and design of the phase III, double-blind, randomised, placebo-controlled EPSILON trial. Neurol Ther 11(3):1409\u20131425","journal-title":"Neurol Ther"},{"key":"3053_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202167","author":"L Guedes","year":"2023","unstructured":"Guedes L, Gra\u00e7a J, Sampaio M, Vieira M, Rocha F, Gama H (2023) Safety of Opicapone after 5 years of post-marketing experience worldwide (P14-11.013). Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000202167","journal-title":"Neurology"},{"issue":"4","key":"3053_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-201X.1998.00319.x","volume":"162","author":"ODLIND Hansell","year":"1998","unstructured":"Hansell ODLIND (1998) Different renal effects of two inhibitors of catechol-O\u2010methylation in the rat: Entacapone and CGP 28014. Acta Physiol Scand 162(4):489\u2013494","journal-title":"Acta Physiol Scand"},{"issue":"10","key":"3053_CR26","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/ene.15990","volume":"30","author":"G Harrison-Jones","year":"2023","unstructured":"Harrison-Jones G, Marston XL, Morgante F, Chaudhuri KR, Castilla\u2010Fern\u00e1ndez G, Di Foggia V (2023) Opicapone versus entacapone: head\u2010to-head retrospective data\u2010based comparison of healthcare resource utilization in people with parkinson\u2019s disease new to catechol\u2010O\u2010methyltransferase (COMT) inhibitor treatment. Eur J Neurol 30(10):3132\u20133141","journal-title":"Eur J Neurol"},{"issue":"10","key":"3053_CR27","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/mc.20432","volume":"47","author":"H Hirata","year":"2008","unstructured":"Hirata H, Hinoda Y, Okayama N et al (2008) COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol Carcinog 47(10):768\u2013774","journal-title":"Mol Carcinog"},{"key":"3053_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/BF00218564","volume":"245","author":"K Inoue","year":"1986","unstructured":"Inoue K, Creveling CR (1986) Immunocytochemical localization of catechol-O-methyltransferase in the oviduct and in macrophages in corpora lutea of rat. Cell Tissue Res 245:623\u2013628","journal-title":"Cell Tissue Res"},{"issue":"5","key":"3053_CR29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pros.20898","volume":"69","author":"K John","year":"2009","unstructured":"John K, Ragavan N, Pratt MM et al (2009) Quantification of phase i\/ii metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon\u2013DNA adduct levels in human prostate. Prostate 69(5):505\u2013519","journal-title":"Prostate"},{"issue":"5","key":"3053_CR30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0306-3623(94)90082-5","volume":"25","author":"S Kaakkola","year":"1994","unstructured":"Kaakkola S, Gordin A, M\u00e4nnist\u00f6 PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. General Pharmacology: The Vascular System 25(5):813\u2013824","journal-title":"General Pharmacology: The Vascular System"},{"key":"3053_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/BF00965786","volume":"5","author":"G Kaplan","year":"1980","unstructured":"Kaplan G, Hartman B, Creveling C (1980) Anti-catechol-O-methyltransferase: demonstration of specificity and immunological cross-reactivity with the enzyme from rat liver, kidney, brain, and choroid plexuses. Neurochem Res 5:869\u2013877","journal-title":"Neurochem Res"},{"issue":"8","key":"3053_CR32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/42.8.8027527","volume":"42","author":"T Karhunen","year":"1994","unstructured":"Karhunen T, Tilgmann C, Ulmanen I, Julkunen I, Panula P (1994) Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 42(8):1079\u20131090","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"3053_CR33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0306-4522(94)90379-4","volume":"62","author":"A Kastner","year":"1994","unstructured":"Kastner A, Anglade P, Bounaix C et al (1994) Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neuroscience 62(2):449\u2013457","journal-title":"Neuroscience"},{"issue":"4","key":"3053_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ane.12278","volume":"130","author":"M Kuoppam\u00e4ki","year":"2014","unstructured":"Kuoppam\u00e4ki M, Vahteristo M, Ellm\u00e9n J, Kieburtz K (2014) Pooled analysis of phase III with Entacapone in P arkinson\u2019s disease. Acta Neurol Scand 130(4):239\u2013247","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"3053_CR35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","volume":"10","author":"J Larsen","year":"2003","unstructured":"Larsen J, Worm-Petersen J, Sid\u00e9n \u00c5 et al (2003) The tolerability and efficacy of Entacapone over 3 years in patients with parkinson\u2019s disease. Eur J Neurol 10(2):137\u2013146","journal-title":"Eur J Neurol"},{"issue":"4","key":"3053_CR36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1212\/WNL.58.4.564","volume":"58","author":"M Lee","year":"2002","unstructured":"Lee M, Kim H, Cho E, Lim J, Rinne J (2002) COMT genotype and effectiveness of Entacapone in patients with fluctuating parkinson\u2019s disease. Neurology 58(4):564\u2013567","journal-title":"Neurology"},{"key":"3053_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14030","author":"JY Lee","year":"2024","unstructured":"Lee JY, Ma H, Ferreira JJ et al (2024) Opicapone to treat early wearing-off in Parkinson\u2019s Disease patients: the Korean ADOPTION trial. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.14030","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"3053_CR38","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JPD-191593","volume":"9","author":"A Lees","year":"2019","unstructured":"Lees A, Ferreira JJ, Rocha J-F et al (2019) Safety profile of Opicapone in the management of Parkinson\u2019s disease. J Parkinsons Dis 9(4):733\u2013740","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"3053_CR39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197\u2013206","journal-title":"JAMA Neurol"},{"key":"3053_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02603-y","author":"V Leta","year":"2023","unstructured":"Leta V, van Wamelen DJ, Aureli F et al (2023) The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson\u2019s disease: opicapone versus entacapone. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-023-02603-y","journal-title":"J Neural Transm"},{"issue":"20","key":"3053_CR41","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1093\/hmg\/ddu268","volume":"23","author":"W Liu","year":"2014","unstructured":"Liu W, Ram\u00edrez J, Gamazon ER et al (2014) Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 23(20):5558\u20135569","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3053_CR42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/dna.1991.10.181","volume":"10","author":"K Lundstr","year":"1991","unstructured":"Lundstr K, Salminen M, Jalanko A, Savolainen R, Ulmanen I (1991) Cloning and characterization of human placental Catechol\u2013Methyltransferase cDNA. DNA Cell Biol 10(3):181\u2013189","journal-title":"DNA Cell Biol"},{"issue":"1","key":"3053_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4838(95)00071-2","volume":"1251","author":"K Lundstr\u00f6m","year":"1995","unstructured":"Lundstr\u00f6m K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Ulmanen I (1995) Cloning, expression and structure of catechol-O-methyltransferase. Biochimica et Biophysica Acta (BBA) 1251(1):1\u201310","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"4","key":"3053_CR44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0031-6997(24)01423-6","volume":"51","author":"PT M\u00e4nnist\u00f6","year":"1999","unstructured":"M\u00e4nnist\u00f6 PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593\u2013628","journal-title":"Pharmacol Rev"},{"key":"3053_CR45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-381326-8.00003-X","volume":"95","author":"TT My\u00f6h\u00e4nen","year":"2010","unstructured":"My\u00f6h\u00e4nen TT, M\u00e4nnist\u00f6 PT (2010) Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? Int Rev Neurobiol 95:29\u201347","journal-title":"Int Rev Neurobiol"},{"issue":"2\u20133","key":"3053_CR46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0014-2999(97)01431-3","volume":"340","author":"E Nissinen","year":"1997","unstructured":"Nissinen E, Kaheinen P, Penttil\u00e4 KE, Kaivola J, Lind\u00e9n I-B (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson\u2019s disease, does not impair mitochondrial energy production. Eur J Pharmacol 340(2\u20133):287\u2013294","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"3053_CR47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0006-8993(96)00790-1","volume":"735","author":"T Nomura","year":"1996","unstructured":"Nomura T, Inoue K, Creveling CR et al (1996) Immunocytochemical localization of aromaticl-amino acid decarboxylase and catechol-O-methyltransferase in blood vessel wall of the human dental pulp. Brain Res 735(2):314\u2013316","journal-title":"Brain Res"},{"key":"3053_CR48","unstructured":"Doc.Ref\u00a0(2004) EMEA\/11854\/04\/Final). Apr\/29th\/2004\u00a0"},{"key":"3053_CR49","doi-asserted-by":"crossref","unstructured":"Poornima R (2016) Critical review of pharmacogenomics bashirs. In: Antiparkinsonian drug therapy: impact on clinical management of parkinson\u2019s disease. Crit Rev 9(6)","DOI":"10.22159\/ajpcr.2016.v9i6.13350"},{"key":"3053_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-020-00187-1","volume":"9","author":"H Reichmann","year":"2020","unstructured":"Reichmann H, Lees A, Rocha J-F, Magalh\u00e3es D, Soares-da-Silva P (2020) Effectiveness and safety of Opicapone in Parkinson\u2019s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener 9:1\u20139","journal-title":"Transl Neurodegener"},{"key":"3053_CR51","volume":"12","author":"J-F Rocha","year":"2021","unstructured":"Rocha J-F, Ebersbach G, Lees A et al (2021) The added benefit of Opicapone when used early in Parkinson\u2019s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and-II. Front Neurol 12:754016","journal-title":"Front Neurol"},{"key":"3053_CR52","doi-asserted-by":"crossref","unstructured":"Roth JA (1992) Membrane-bound catechol-O-methyltransferase: a Reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Springer","DOI":"10.1007\/BFb0036121"},{"issue":"2","key":"3053_CR53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-1119(90)90231-F","volume":"93","author":"M Salminen","year":"1990","unstructured":"Salminen M, Lundstr\u00f6m K, Tilgmann C, Savolainen R, Kalkkinen N, Ulmanen I (1990) Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 93(2):241\u2013247","journal-title":"Gene"},{"key":"3053_CR54","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Zhang J, Xue T et al (2021) Different catechol-o-methyl transferase inhibitors in Parkinson\u2019s disease: a bayesian network meta-analysis. Front Neurol 12:707723","journal-title":"Front Neurol"},{"issue":"1","key":"3053_CR55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0304-3835(99)00197-4","volume":"144","author":"J Tenhunen","year":"1999","unstructured":"Tenhunen J, Heikkil\u00e4 P, Alanko A, Heinonen E, Akkila J, Ulmanen I (1999) Soluble and membrane-bound catechol-O-methyltransferase in normal and malignant mammary gland. Cancer Lett 144(1):75\u201384","journal-title":"Cancer Lett"},{"issue":"13","key":"3053_CR56","doi-asserted-by":"crossref","first-page":"e1487","DOI":"10.1212\/WNL.0000000000007173","volume":"92","author":"C Trenkwalder","year":"2019","unstructured":"Trenkwalder C, Kuoppam\u00e4ki M, Vahteristo M, M\u00fcller T, Ellm\u00e9n J (2019) Increased dose of carbidopa with levodopa and entacapone improves off time in a randomized trial. Neurology 92(13):e1487\u2013e1496","journal-title":"Neurology"},{"issue":"8","key":"3053_CR57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/bmc.202","volume":"16","author":"M Tsunoda","year":"2002","unstructured":"Tsunoda M, Takezawa K, Masuda M, Imai K (2002) Rat liver and kidney catechol-O\u2010methyltransferase activity measured by high\u2010performance liquid chromatography with fluorescence detection. Biomed Chromatogr 16(8):536\u2013541","journal-title":"Biomed Chromatogr"},{"issue":"13","key":"3053_CR58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137213","volume":"22","author":"V Vuleti\u0107","year":"2021","unstructured":"Vuleti\u0107 V, Ra\u010dki V, Papi\u0107 E, Peterlin B (2021) A systematic review of Parkinson\u2019s disease pharmacogenomics: is there time for translation into the clinics? Int J Mol Sci 22(13):7213","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03053-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:19:05Z","timestamp":1792577945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03053-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03053-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pasquale Maria Pecoraro, Simona Paola Carbone, Francesco Bugamelli report no competing interests. Lazzaro di Biase reports a relationship with Bial that includes: consulting or advisory. Lazzaro di Biase reports a relationship with AbbVie Inc that includes: consulting or advisory. Lazzaro di Biase reports a relationship with Boston Scientific Corp that includes: consulting or advisory. Lazzaro di Biase reports a relationship with Zambon SpA that includes: funding grants. Lazzaro di Biase reports a relationship with Brain Innovations that includes: equity or stocks.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study has no registration number.","order":2,"name":"Ethics","label":"Registration number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}